Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment
Alimentary Pharmacology & Therapeutics2019Vol. 49(11), pp. 1385–1394
Citations Over TimeTop 1% of 2019 papers
Qi Chen, Xiaohua Long, Yingjie Ji, Xiao Liang, Dongping Li, Hong Gao, Beili Xu, Ming Liu, Ying Chen, Yunwei Sun, Yan Zhao, Gang Xu, Yanyan Song, Lou Yu, Wei Zhang, Wenzhong Liu, David Y. Graham, Hong Lü
Abstract
Both susceptibility-guided and empiric therapies provided excellent eradication rates. Clinically, the choice would hinge on availability of susceptibility testing and/or a locally highly effective empiric therapy.
Related Papers
- → Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis(2021)27 cited
- → Variability in Prevalence ofHelicobacter pyloriStrains Resistant to Clarithromycin and Levofloxacin in Southern Poland(2012)23 cited
- → Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? authors’ reply(2010)14 cited
- → Levofloxacin‐based Helicobacter pylori eradication in chronic dyspepsia(2021)5 cited
- → Clarithromycin-based therapy of Helicobacter pylori in Iran(2017)2 cited